TS8A Stock Chart & Stats
€5.00
-€0.35(-4.52%)
At close: 4:00 PM EST
€5.00
-€0.35(-4.52%)
Day’s Range― - ―
52-Week Range€4.34 - €6.90
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€64.64M
Enterprise Value€229.80
Total Cash (Recent Filing)€131.00K
Total Debt (Recent Filing)€145.58M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Jul 29, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding14,493,035
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)0.72
Price to Sales (P/S)0.24
P/FCF Ratio3.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.77Price Target Upside75.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)€199.91M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationSustained positive operating and free cash flow provides durable internal liquidity to fund bid costs, invest in capabilities, and pay down debt. Even with declining revenue, consistent cash generation supports financial flexibility and reduces reliance on external financing over the next several quarters.
Margin ResilienceMaintaining a roughly 9% adjusted EBITDA margin despite sharp top-line declines indicates disciplined cost management and a scalable cost base. This structural margin durability supports cash conversion and targeted deleveraging, helping preserve credit standing during contract timing volatility.
Contract Visibility And PipelineA sole-source NIH extension plus an improving federal pipeline provide recurring revenue buckets and increased award opportunity. Structural contract wins and visible task orders underpin medium-term revenue recovery prospects and improve predictability versus one-off project cycles.
Bears Say
Revenue Decline And Net LossSustained revenue contraction and a recent net loss erode earnings power and reduce margins available to service debt or fund growth. If revenue stabilization lags, operating leverage will continue to compress profitability and constrain reinvestment and bidding capacity across federal procurements.
Elevated LeverageMaterial leverage, even after partial deleveraging, limits financial flexibility and raises refinancing and covenant risk if earnings remain weak. Higher interest and principal amortization pressures long-term cash allocation, making sustained margin and cash conversion critical to avoid further strain.
Small-business Transitions And Program LossesLoss of legacy program volume to small-business set-asides is a structural revenue headwind that reduces predictable contract tenure and scale. Replacing steady, long-term work with competitive recompetes increases revenue volatility and makes growth dependent on winning new IDIQ task orders and recompetes.
DLH Holdings News
TS8A FAQ
What was DLH Holdings’s price range in the past 12 months?
DLH Holdings lowest stock price was €4.34 and its highest was €6.90 in the past 12 months.
What is DLH Holdings’s market cap?
DLH Holdings’s market cap is €64.64M.
When is DLH Holdings’s upcoming earnings report date?
DLH Holdings’s upcoming earnings report date is Jul 29, 2026 which is in 2 days.
How were DLH Holdings’s earnings last quarter?
DLH Holdings released its earnings results on May 06, 2026. The company reported -€0.149 earnings per share for the quarter, missing the consensus estimate of -€0.141 by -€0.009.
Is DLH Holdings overvalued?
According to Wall Street analysts DLH Holdings’s price is currently Undervalued.
Does DLH Holdings pay dividends?
DLH Holdings does not currently pay dividends.
What is DLH Holdings’s EPS estimate?
DLH Holdings’s EPS estimate is -0.15.
How many shares outstanding does DLH Holdings have?
DLH Holdings has 14,493,035 shares outstanding.
What happened to DLH Holdings’s price movement after its last earnings report?
DLH Holdings reported an EPS of -€0.149 in its last earnings report, missing expectations of -€0.141. Following the earnings report the stock price went down -0.422%.
Which hedge fund is a major shareholder of DLH Holdings?
Currently, no hedge funds are holding shares in DE:TS8A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DLH Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€8.77 (75.41% Upside)
€8.77 (75.41% Upside)
Insider Transactions
Bought Shares
Worth €813.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.75%
Trailing 12-Months
Company Description
DLH Holdings
DLH Holdings Corp., headquartered in Atlanta, Georgia, was established in 1969 and operated as TeamStaff, Inc. until its name change in June 2012. The company specializes in offering a range of technology-enabled business process outsourcing, comprehensive program management solutions, and public health research and analytics services throughout the United States, with a primary focus on the federal health services market. A significant portion of DLH's work involves defense and veterans' health, where it delivers integrated healthcare, technology, and logistical support. Key clients in this sector include the Department of Veterans Affairs (VA), the Defense Health Agency, the Tele-medicine and Advanced Technology Research Center, the Navy Bureau of Medicine and Surgery, and the Army Medical Research and Material Command. Additionally, the company provides diverse human services and solutions, covering areas such as rigorous monitoring and evaluation, efficient electronic medical records migration, robust data collection and management, and thorough nutritional and social health assessments. It also offers expert IT system architecture design, strategic migration planning, and continuous maintenance services. In the sphere of public health and life sciences, DLH undertakes crucial initiatives like clinical trials, epidemiological studies, and disease prevention. It actively promotes health among underserved and at-risk communities through the creation of impactful strategic communication campaigns, research into emerging health trends, in-depth health informatics analyses, and the application of proven best practices.
TS8A Company Deck
TS8A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated a mixed picture: material near-term financial headwinds with a steep year-over-year revenue decline (~33.5%) and a sharp drop in adjusted EBITDA (~43.6%), largely driven by program transitions to small business set-asides and contract completions. Offsetting these negatives, management reported margin resilience (9% adjusted EBITDA margin), positive free cash flow (~$3.8M), resumed deleveraging (debt reduced to $132.7M), a two-year NIH contract extension adding revenue visibility, recognition for technology capabilities, and an improving pipeline as delayed procurements return to market. Risks remain around federal health reprioritization and typical government procurement timing uncertainty, but the company appears to be stabilizing its cost structure and positioning for upcoming opportunities.View all DE:TS8A earnings summariesTS8A Stock 12 Month Forecast
Average Price Target
€8.77
▲(75.41% Upside)